Advertisement
ADMA vs NVAX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a Buy and NVAX is a Hold.
Aroon Indicator for ADMA shows an upward move is likely
ADMA's Aroon Indicator triggered a bullish signal on October 30, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 254 similar instances where the Aroon Indicator showed a similar pattern. In 210 of the 254 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for ADMA crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +5.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in 245 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for ADMA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 28 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
ADMA broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.261) is normal, around the industry mean (3.162). P/E Ratio (15.847) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (4.170) is also within normal values, averaging (439.647).
Momentum Indicator for NVAX turns negative, indicating new downward trend
NVAX saw its Momentum Indicator move below the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 77 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for NVAX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 38 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
NVAX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on October 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NVAX broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 58 cases where NVAX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The 50-day moving average for NVAX moved above the 200-day moving average on September 24, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in 193 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 91 of 116 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.718) is normal, around the industry mean (3.162). P/E Ratio (-6.588) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (3.759) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ADMA | NVAX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 61 | 100 | |
SMR RATING 1..100 | 25 | 100 | |
PRICE GROWTH RATING 1..100 | 41 | 41 | |
P/E GROWTH RATING 1..100 | 59 | 99 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVAX's Valuation (9) in the Biotechnology industry is significantly better than the same rating for ADMA (86). This means that NVAX’s stock grew significantly faster than ADMA’s over the last 12 months.
ADMA's Profit vs Risk Rating (61) in the Biotechnology industry is somewhat better than the same rating for NVAX (100). This means that ADMA’s stock grew somewhat faster than NVAX’s over the last 12 months.
ADMA's SMR Rating (25) in the Biotechnology industry is significantly better than the same rating for NVAX (100). This means that ADMA’s stock grew significantly faster than NVAX’s over the last 12 months.
ADMA's Price Growth Rating (41) in the Biotechnology industry is in the same range as NVAX (41). This means that ADMA’s stock grew similarly to NVAX’s over the last 12 months.
ADMA's P/E Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for NVAX (99). This means that ADMA’s stock grew somewhat faster than NVAX’s over the last 12 months.
| ADMA | NVAX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 72% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 86% |
| Momentum ODDS (%) | N/A | 2 days ago 90% |
| MACD ODDS (%) | N/A | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 85% |
| Advances ODDS (%) | 3 days ago 82% | 3 days ago 80% |
| Declines ODDS (%) | 9 days ago 74% | 6 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 78% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADMA’s FA Score shows that 1 FA rating(s) are green while NVAX’s FA Score has 1 green FA rating(s).
- ADMA’s FA Score: 1 green, 4 red.
- NVAX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADMA’s TA Score shows that 3 TA indicator(s) are bullish while NVAX’s TA Score has 4 bullish TA indicator(s).
- ADMA’s TA Score: 3 bullish, 4 bearish.
- NVAX’s TA Score: 4 bullish, 7 bearish.
Price Growth
ADMA (@Biotechnology) experienced а +6.84% price change this week, while NVAX (@Biotechnology) price change was +3.92% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
Reported Earning Dates
ADMA is expected to report earnings on Nov 04, 2026.
NVAX is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ADMA and
Correlation & Price change
A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with ENGN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then ENGN could also see price increases.
| Ticker / NAME | Correlation To ADMA | 1D Price Change % | ||
|---|---|---|---|---|
| ADMA | 100% | -2.89% | ||
| ENGN - ADMA | 36% Loosely correlated | N/A | ||
| VCYT - ADMA | 36% Loosely correlated | -4.14% | ||
| MAZE - ADMA | 35% Loosely correlated | -1.41% | ||
| AMRN - ADMA | 34% Loosely correlated | -4.91% | ||
| TAOX - ADMA | 33% Loosely correlated | -10.44% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CDX | 20.19 | 0.03 | +0.15% |
| Simplify High Yield ETF (CDX) | |||
| PAYR | 56.57 | 0.04 | +0.07% |
| Federated Hermes Enhanced Income ETF (PAYR) | |||
| AURU | 11.71 | N/A | N/A |
| Tradr 2X Long AUR Daily ETF | |||
| MLRG | 104.67 | -1.94 | -1.82% |
| iShares MSCI USA ETF (MLRG) | |||
| ONDG | 1.49 | -0.31 | -17.22% |
| Leverage Shares 2X Long ONDS Daily ETF (ONDG) | |||